CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aerie Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aerie Pharmaceuticals Inc
4301 Emperor Boulevard, Suite 400
Phone: (919) 237-5300p:919 237-5300 DURHAM, NC  27703  United States Fax: (908) 470-4329f:908 470-4329
This company was Merged or Acquired on 11/17/2022.
This company ceased filing statements with the SEC on 12/1/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Aerie Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The Company's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director RajKannan 58 12/20/2021 12/20/2021
Co-Founder, Chief Innovation Officer, Head of Research and External Innovation Casey C.Kopczynski 60 3/1/2022 1/1/2005
Chief Financial Officer Peter F.Lang 50 3/18/2022 3/18/2022
7 additional Officers and Directors records available in full report.

Business Names
Business Name
AERI
Aerie Distribution Inc.
Aerie Pharmaceuticals Ireland Limited
Aerie Pharmaceuticals Limited
AVIZOREX PHARMA SL.

General Information
Number of Employees: 376 (As of 12/31/2021)
Outstanding Shares: 49,417,407 (As of 10/28/2022)
Shareholders: 207
Stock Exchange: NASD
Federal Tax Id: 203109565
Fax Number: (908) 470-4329


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, March 23, 2024